Future oncology (London, England) · 2025
Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Duan Yanan, Cheng Shuping, Qin Wenru, Zou Bing, Fan Bingjie, Wang Linlin
Аннотация
BACKGROUND: This study assessed the efficacy and safety of radiotherapy (RT) plus immunochemotherapy in oligometastatic esophageal cancer (OMEC).
METHODS: A single-center retrospective study of OMEC patients who received immunochemotherapy from Jan 2019 to Jan 2022.
RESULTS: About 226 patients were included, which consisted of 108 cases in the RT plus immunochemotherapy group (iCRT), and 118 cases in the immunochemotherapy group (iCT). With a median follow-up of 22.2 months, the median progression-free survival (PFS) was 13.0 months for the iCRT group and 7.7 months for the iCT group (p < 0.001, HR = 0.520, 95%CI, 0.388-0.696). The median overall survival (OS) was 27.5 months for the iCRT group and 21.7 months for the iCT group (p = 0.026, HR = 0.670, 95%CI, 0.468-0.958). The iCRT group was associated with a higher risk of ≥grade 3 myelosuppression. No grade 5 treatment-related adverse events were observed. Univariate and multivariate analysis showed that a history of alcohol consumption, more metastatic lesions, and second-line and above treatment had inferior PFS in OMEC patients. A lower Karnofsky performance status score, more metastatic lesions, and second-line and above treatment were found to have inferior OS.
CONCLUSION: Compared to immunochemotherapy alone, RT plus immunochemotherapy showed survival benefits with manageable safety for OMEC patients.
METHODS: A single-center retrospective study of OMEC patients who received immunochemotherapy from Jan 2019 to Jan 2022.
RESULTS: About 226 patients were included, which consisted of 108 cases in the RT plus immunochemotherapy group (iCRT), and 118 cases in the immunochemotherapy group (iCT). With a median follow-up of 22.2 months, the median progression-free survival (PFS) was 13.0 months for the iCRT group and 7.7 months for the iCT group (p < 0.001, HR = 0.520, 95%CI, 0.388-0.696). The median overall survival (OS) was 27.5 months for the iCRT group and 21.7 months for the iCT group (p = 0.026, HR = 0.670, 95%CI, 0.468-0.958). The iCRT group was associated with a higher risk of ≥grade 3 myelosuppression. No grade 5 treatment-related adverse events were observed. Univariate and multivariate analysis showed that a history of alcohol consumption, more metastatic lesions, and second-line and above treatment had inferior PFS in OMEC patients. A lower Karnofsky performance status score, more metastatic lesions, and second-line and above treatment were found to have inferior OS.
CONCLUSION: Compared to immunochemotherapy alone, RT plus immunochemotherapy showed survival benefits with manageable safety for OMEC patients.